# Phase III Study of KX-826 With Adult Male Patients With AGA

> **NCT06126965** · PHASE3 · UNKNOWN · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 740 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** KX-826-（5%） BID
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06126965
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-29
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 740 (ACTUAL)
- **Last updated:** 2024-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126965, "Phase III Study of KX-826 With Adult Male Patients With AGA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06126965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*